VEGFA and hereditary hemorrhagic telangiectasia: Of these potential approaches, only anti-VEGF targeting and thalidomide-related drugs are currently being used in the clinic to treat HHT, and their use predated our current conceptual understanding of their protective mechanisms in HHT.